Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 4/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | GALR3 | O60755 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82273 | 1.00 | ALDH1A1 (0.54) | ALDH1A1KDM4EPOLBSMN1; SMN2ESR1 | |
| SCHEMBL6428557 | 0.90 | ALDH1A1 (0.48) | ALDH1A1KDM4EPOLBSMN1; SMN2ESR1 | |
| SCHEMBL574298 | 0.83 | ALOX5 (0.50) | ALDH1A1KDM4EPOLBSMN1; SMN2ESR1 | |
| SCHEMBL28145390 | 0.82 | ALDH1A1 (0.51) | ALDH1A1KDM4EPOLBSMN1; SMN2HPGD | |
| SCHEMBL1005997 | 0.82 | ALOX15 (0.44) | ALDH1A1KDM4EPOLBSMN1; SMN2ESR1 | |
| SCHEMBL30777878 | 0.82 | ALOX15 (0.44) | ALDH1A1KDM4EPOLBSMN1; SMN2ESR1 | |
| SCHEMBL68224 | 0.81 | ALOX15 (0.54) | ALDH1A1KDM4EPOLBSMN1; SMN2HPGD | |
| SCHEMBL4813970 | 0.81 | ALDH1A1 (0.61) | ALDH1A1KDM4EPOLBSMN1; SMN2HPGD | |
| SCHEMBL1821570 | 0.79 | HPGD (0.47) | ALDH1A1KDM4EPOLBSMN1; SMN2HPGD | |
| SCHEMBL573894 | 0.79 | TYR (0.52) | ALDH1A1KDM4EPOLBSMN1; SMN2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4694889-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN AGGREGATION DISEASES | Acelot, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| EP-4551195-A1 | CANNABINOID LIPID PREMIXTURE | Fertin Pharma A/S (DK) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025067622-A1 | CANNABIDIOL FOR USE IN ALLEVIATING XEROSTOMIA | FERTIN PHARMA A/S (DK) | 2025-04-03 | — | — | WO | disclosed |
| EP-3769624-B1 | ENHANCING THE ANTIMICROBIAL ACTIVITY OF BIOCIDES WITH POLYMERS | BASF SE (DE) | 2024-10-30 | — | — | EP | disclosed |
| WO-2024216203-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN AGGREGATION DISEASES | ACELOT, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| WO-2024008261-A1 | CANNABINOID LIPID PREMIXTURE | FERTIN PHARMA A/S (DK) | 2024-01-11 | — | — | WO | disclosed |
| US-11666050-B2 | Enhancing the antimicrobial activity of biocides with polymers | BASF SE (DE) | 2023-06-06 | — | — | US | disclosed |
| US-11647746-B2 | Enhancing the antimicrobial activity of biocides with polymers | BASF SE (DE) | 2023-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11647746-B2 | Enhancing the antimicrobial activity of biocides with polymers | CAT, AOC1, DDT | ALDH1A1 787/4885KDM4E 2071/4885POLB 92/4885 |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | ALDH1A1 128/4885KDM4E 3895/4885POLB 3098/4885 |
| US-11666050-B2 | Enhancing the antimicrobial activity of biocides with polymers | CAT, AOC1, DDT | ALDH1A1 787/4885KDM4E 2071/4885POLB 92/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | ALDH1A1 128/4885KDM4E 3895/4885POLB 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.